US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NanoViricides

1.58

-0.1050-6.25%

Volume:849.38K

Turnover:1.34M

Market Cap:25.31M

PE:-2.29

High:1.62

Open:1.61

Low:1.55

Close:1.68

Loading ...

Overview Company News Filings

NanoViricides Inc. Announces Breakthrough in Measles Treatment with Successful NV-387 Animal Trials

NanoViricides Inc. Announces Phase II Clinical Trial for NV-387 to Combat MPox Epidemic

NanoViricides: Design of Adaptive Clinical Trial Protocol for Treatment of Mpox Virus Clade Ia and Ib Infections and Disease Is Nearly Complete

THOMSON REUTERS

NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387

NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPox Infection

NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387

NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks

Nanoviricides Q3 GAAP EPS $(0.14) Up From $(0.16) YoY

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

ACCESS Newswire

NanoViricides Inc: Begun Evaluation of Its Clinical Drug Nv-387 for Treatment of Measles Virus

THOMSON REUTERS

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

ACCESS Newswire

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

ACCESS Newswire

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

ACCESS Newswire

NanoViricides reports Q2 EPS (14c) vs. (18c) last year

NanoViricides, Inc. Has Filed its Quarterly Report

ACCESS Newswire

NanoViricides: Fiscal Q2 Earnings Snapshot

Associated Press Finance

Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

ACCESS Newswire

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

ACCESS Newswire

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NNVC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NNVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NNVC\",,,,,undefined,":{"symbol":"NNVC","market":"US","secType":"STK","nameCN":"NanoViricides","latestPrice":1.575,"timestamp":1753107886685,"preClose":1.68,"halted":0,"volume":849377,"delay":0,"floatShares":15504698,"shares":16072000,"eps":-0.688325,"marketStatus":"Trading","change":-0.105,"latestTime":"07-21 10:24:53 EDT","open":1.6101,"high":1.6232,"low":1.545,"amount":1341932.7608047999,"amplitude":0.046548,"askPrice":1.59,"askSize":300,"bidPrice":1.57,"bidSize":113,"shortable":3,"etf":0,"ttmEps":-0.688325,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1753128000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380081600000,"exchange":"AMEX","adjPreClose":1.68,"preHourTrading":{"tag":"盘前","latestPrice":1.62,"preClose":1.68,"latestTime":"09:29 EDT","volume":210820,"amount":375983.66129,"timestamp":1753104567379},"postHourTrading":{"tag":"盘后","latestPrice":1.59,"preClose":1.68,"latestTime":"19:57 EDT","volume":2467,"amount":3978.93,"timestamp":1752883060107},"volumeRatio":14.730756,"impliedVol":0.6812,"impliedVolPercentile":0.552},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NNVC\",,,,,undefined,":{"symbol":"NNVC","floatShares":15504698,"roa":"-57.38%","roe":"-99.84%","lyrEps":-0.698686,"volumeRatio":14.730756,"shares":16072000,"dividePrice":0,"high":1.6232,"amplitude":0.046548,"preClose":1.68,"low":1.545,"week52Low":0.94,"pbRate":"2.87","week52High":2.55,"institutionHeld":0,"latestPrice":1.575,"committee":-0.452785,"eps":-0.688325,"divideRate":0,"volume":849377,"delay":0,"ttmEps":-0.688325,"open":1.6101,"prevYearClose":1.43,"prevWeekClose":1.68,"prevMonthClose":1.4,"prevQuarterClose":1.4,"fiveDayClose":1.6,"twentyDayClose":1.43,"sixtyDayClose":1.3336},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NNVC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553017473","title":"NanoViricides Inc. Announces Breakthrough in Measles Treatment with Successful NV-387 Animal Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2553017473","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553017473?lang=en_us&edition=fundamental","pubTime":"2025-07-21 18:30","pubTimestamp":1753093823,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical stage company specializing in broad-spectrum antivirals, has announced promising results from their recent animal study involving NV-387, a drug candidate aimed at treating Measles. The study utilized humanized mice to simulate Measles infection, as the virus does not naturally infect mice. NV-387 demonstrated a significant increase in survival rates, extending the average lifespan of infected animals from 7.4 days to 17 days, without any observed toxicity. The drug, designed to mimic cellular features essential for viral binding, showed a dose-dependent improvement in survival. These results indicate NV-387's potential as the first drug to effectively treat Measles, as global cases continue to rise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL2xs61k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2551284411","title":"NanoViricides Inc. Announces Phase II Clinical Trial for NV-387 to Combat MPox Epidemic","url":"https://stock-news.laohu8.com/highlight/detail?id=2551284411","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551284411?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:33","pubTimestamp":1752669220,"startTime":"0","endTime":"0","summary":"NanoViricides, Inc., a clinical-stage company specializing in broad-spectrum antiviral therapies, has announced the development of a clinical trial protocol for a Phase II study of NV-387, aimed at treating MPox disease in the African region. This randomized clinical trial will compare NV-387 treatment with the standard of care to evaluate the dosing regimen's safety, tolerability, and effectiveness against the MPXV virus. The trial comes in response to the ongoing MPox epidemic and the extension of the Public Health Emergency of International Concern  by the World Health Organization. No results from this impending study have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL50npL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2551907480","title":"NanoViricides: Design of Adaptive Clinical Trial Protocol for Treatment of Mpox Virus Clade Ia and Ib Infections and Disease Is Nearly Complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551907480?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:32","pubTimestamp":1752489168,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3T905H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2551907464","title":"NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551907464?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:30","pubTimestamp":1752489033,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a publicly traded company focused on developing broad-spectrum antivirals, has announced that the design of its adaptive clinical trial protocol for treating MPox Virus Clade Ia and Ib infections with the novel drug NV-387 is nearing completion. The trial aims to gather data on safe and effective dosing regimens, the safety and tolerability of the drug, and its antiviral effectiveness. The adaptive, randomized, standard of care controlled trial will enroll approximately 80 patients and proceed in two parts. In the Phase IIa part, NV-387 will be compared with the standard of care over an initial six-day dosing period, with potential for extension based on patient outcomes. Currently, no drug is approved as effective for treating MPox. If NV-387 proves effective, it would be the first drug to demonstrate effectiveness against an orthopoxvirus in human clinical trials. Results of the trial are expected to provide crucial insights into the drug's safety and efficacy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL6lCy3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","NNVC"],"gpt_icon":0},{"id":"2548300869","title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 Targeting MPox Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2548300869","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548300869?lang=en_us&edition=fundamental","pubTime":"2025-07-01 18:41","pubTimestamp":1751366491,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a publicly traded company specializing in the development of broad-spectrum antivirals, has announced the progression of its lead candidate, NV-387, into Phase II clinical trials for the treatment of MPox infection. This decision follows substantial efficacy data in animal studies for multiple indications, including RSV, Influenza, COVID, and Orthopoxviruses. The company has engaged a Clinical Research Organization to conduct the trial, with a site established in the Democratic Republic of Congo. The Clinical Trial Application is nearing completion, and manufacturing of the NV-387 substance is largely finished. The trial aims to expedite the company's pipeline towards revenue generation, with plans to extend NV-387's application to respiratory infections following the MPox trial. Results from this clinical study have yet to be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL4h0yG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2540050346","title":"NanoViricides Inc. Announces Imminent Animal Study for Promising Measles Drug Candidate NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050346?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:55","pubTimestamp":1749034520,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a clinical-stage company specializing in broad-spectrum antivirals, has announced the imminent commencement of an animal study for its Measles drug development program. The study will evaluate drug candidates in a lethal animal infection model, using specially modified mice that express the human CD150/SLAM protein, necessary for Measles virus entry into cells. The company is advancing its drug NV-387, which previously demonstrated efficacy against RSV in animals and may show similar effectiveness against Measles. NV-387 acts by mimicking cell features to bind and destroy viruses. The study aims to assess NV-387's potential for treating Measles, addressing a growing need as current Measles genotypes drift from existing vaccine strains. There is currently no approved drug for Measles, with Vitamin A and ribavirin being used in specific cases. Results from this study will inform the potential human application of NV-387.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL47VQjN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NNVC","BK4568"],"gpt_icon":0},{"id":"2535239833","title":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks","url":"https://stock-news.laohu8.com/highlight/detail?id=2535239833","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535239833?lang=en_us&edition=fundamental","pubTime":"2025-05-16 18:31","pubTimestamp":1747391489,"startTime":"0","endTime":"0","summary":"NanoViricides Inc. Announces Phase II Clinical Trial for Broad-Spectrum Antiviral NV-387 to Combat MPox and Measles Outbreaks. NanoViricides Inc. has announced the advancement of its broad-spectrum antiviral drug candidate, NV-387, into Phase II clinical trials. The trials aim to evaluate the drug's effectiveness in treating MPox infections, a pressing medical need given the ongoing pandemic in Africa and spillover cases globally. NV-387 has previously demonstrated promising results in animal models against various viruses, including RSV, Influenza, and Poxviruses. Additionally, the company is preparing for Phase II trials targeting Viral Acute and Severe Acute Respiratory Infections. NanoViricides is also exploring NV-387's potential against Measles and Bird Flu. The company reported financial constraints but plans to secure funding through equity markets and partnerships to continue its development objectives.Disclaimer: This news brief was created by Public Technologies  using gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL4Rpq2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4139","BK4568"],"gpt_icon":0},{"id":"2535122806","title":"Nanoviricides Q3 GAAP EPS $(0.14) Up From $(0.16) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535122806","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535122806?lang=en_us&edition=fundamental","pubTime":"2025-05-16 05:44","pubTimestamp":1747345464,"startTime":"0","endTime":"0","summary":"Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.14) per share. This is a 12.5 percent increase over losses of $(0.16) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45456458/nanoviricides-q3-gaap-eps-0-14-up-from-0-16-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC"],"gpt_icon":0},{"id":"2533586096","title":"NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC","url":"https://stock-news.laohu8.com/highlight/detail?id=2533586096","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533586096?lang=en_us&edition=fundamental","pubTime":"2025-05-05 18:30","pubTimestamp":1746441000,"startTime":"0","endTime":"0","summary":"Shelton, Connecticut-- - NanoViricides, Inc. , , a leading clinical stage global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Anil R. Diwan, President & Executive Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. .To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nanoviricides-inc-announces-participation-d-103000436.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-inc-announces-participation-d-103000436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4233","ET","BK4590","BK4585","BK4139","BK4561","BK4588","NYC","BK4581","NNVC","BK4568","BK4144","BK4160"],"gpt_icon":0},{"id":"2531816517","title":"Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It","url":"https://stock-news.laohu8.com/highlight/detail?id=2531816517","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531816517?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:30","pubTimestamp":1745922600,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company  , and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, provides further details on its Measles drug development program herewith.To date, only effective drugs have brought or maintained endemic or circulating viruses under control. There are no vaccines for herpes viruses, HIV or hepatitis C virus. Yet, successful drugs have helped patients to be cured , or recover from episodes , or at least maintain healthy lifespan  without any vaccines.Although there is a successful vaccine for measles, there are several reasons why vaccination rates are declining. First and foremost is the fear of side effects. Even if the side effects are uncommon, what parents would want their child to become part of the unfortunate statistic?Secondly, there is a lack of public trust fomented by the aggressive and dogmat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/measles-likely-become-endemic-nanoviricides-103000449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2527134008","title":"NanoViricides Inc: Begun Evaluation of Its Clinical Drug Nv-387 for Treatment of Measles Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2527134008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527134008?lang=en_us&edition=fundamental","pubTime":"2025-04-14 18:32","pubTimestamp":1744626768,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nFWN3QQ04Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2527430155","title":"Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak","url":"https://stock-news.laohu8.com/highlight/detail?id=2527430155","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527430155?lang=en_us&edition=fundamental","pubTime":"2025-04-14 18:30","pubTimestamp":1744626600,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company  , and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has begun evaluation of its clinical drug NV-387 for the treatment of the Measles virus.NanoViricides is open to enabling use of NV-387 to combat Measles virus infection in hospitalized patients and welcomes inquiries that are consistent with current FDA regulatory requirements under \"Emergency Expanded Access for an Individual Patient\" and under \"Expanded Access for an Individual Patient\".The Company has planned additional laboratory studies to evaluate the effectiveness of NV-387 against Measles virus infection in cell culture and animal models to support a future IND application, although we believe the results of these studies would not be required for use of NV-387 under FDA regulations pertaining to \"Emergency ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/measles-outbreak-expands-begging-drug-103000782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NNVC","BK4568"],"gpt_icon":0},{"id":"2518147107","title":"NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2518147107","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518147107?lang=en_us&edition=fundamental","pubTime":"2025-03-11 18:30","pubTimestamp":1741689000,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. , a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its business is not affected by the tariff policies of the US government or corresponding retaliatory policies of other governments, nor is it affected by the spending cuts being implemented by the current White House administration.Therefore, the Company believes that smart financial strategists would view the longer term strong prospects of the Company  as supporting the case of NNVC as an effective hedge against the current general stock market turmoil.\"We believe that the policies of the current Secretary of HHS, Mr. Robert F. Kennedy, would lead to focusing more strongly on development of broad-spectrum antiviral treatments such as our clinical-stage as well as earlier-stage antiviral pipeline drug products rather than the previous vaccine-focused strategy,\" said Anil R. Diw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-not-affected-tariffs-other-103000613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2516271126","title":"Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2516271126","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516271126?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:30","pubTimestamp":1741087800,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled \"Measles outbreak is call to action for all of us\". He identifies an important issue that, \"…there is no approved antiviral for those who may be infected…\"We applaud Secretary Kennedy for recognizing the urgency of the situation and taking all possible steps including promoting vaccination in response to this outbreak, while clearly recognizing the deficiency in the response to be the lack of an effective treatment for measles viral disease,\" said Anil R. Diwan, PhD., President of NanoViricides, Inc.We note that the current efforts at containment with case-tracking, contact-tracing and isolation, face daunting challenges to be effective because measles is far more contagious than SARS-CoV-2 that caused the global COVID pandemic. In fact, measles is the most contagious disease known to humans. Also, a person may be contagious several days befo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/measles-outbreak-nv-387-promises-113000537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","NNVC","HHS","BK4009","BK4139"],"gpt_icon":0},{"id":"2512101445","title":"NanoViricides reports Q2 EPS (14c) vs. (18c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101445?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:50","pubTimestamp":1739969423,"startTime":"0","endTime":"0","summary":"The company said, “We reported that, as of December 31, 2024, we had cash and cash equivalent current assets balance of approximately $3.96 Million...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nanoviricides-reports-q2-eps-14c-vs-18c-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nanoviricides-reports-q2-eps-14c-vs-18c-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NNVC"],"gpt_icon":0},{"id":"2512810520","title":"NanoViricides, Inc. Has Filed its Quarterly Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2512810520","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512810520?lang=en_us&edition=fundamental","pubTime":"2025-02-19 19:30","pubTimestamp":1739964600,"startTime":"0","endTime":"0","summary":"Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu. We reported that, as of December 31, 2024, we had cash and cash equivalent current assets balance of approximately $3.96 Million. In addition, we reported approximately $7.17 Million in Net Property and Equipment (P&E) assets . The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.18 Million.The net cash utilized during the six months ended December 31, 2024 was approximately $4.79 million. This included certain non-recurring expenditures including R&D expenditures in preparation for a Phase II clinical trial application. We raised approximately $4 million net of commission and certain expenses in an At-the-Market offering  during the six months ended December 31, 2024.There is no drug available for the treatment of MPox infection. The MPox Clade 1/1b has a substantially g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-inc-filed-quarterly-report-113000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2511610418","title":"NanoViricides: Fiscal Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2511610418","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511610418?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:37","pubTimestamp":1739569040,"startTime":"0","endTime":"0","summary":"SHELTON, Conn.  — SHELTON, Conn.  — NanoViricides Inc.  on Friday reported a loss of $2 million in its fiscal second quarter.On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 14 cents.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-fiscal-q2-earnings-snapshot-213720728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NNVC"],"gpt_icon":0},{"id":"2511645049","title":"Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511645049","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511645049?lang=en_us&edition=fundamental","pubTime":"2025-02-15 00:29","pubTimestamp":1739550576,"startTime":"0","endTime":"0","summary":"We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at where NanoViricides Inc.  stands against other best nanotech penny stocks to invest in.Nanotech involves working with tiny particles which are about the size of molecules. This field is being used to improve products in many different industries, like electronics, medicine, and energy. By manipulating matter at this tiny scale, materials and devices with special properties can be made. The global nanotech market was valued at $3.69 billion in 2022 and is projected to grow at a 33.1% CAGR from 2023 to 2030, as reported by Grand View Research. This is driven by the increased use in medical diagnostics and imaging, technological advancements, substantial R&D funding, and the creation of advanced materials for healthcare, electronics, aerospace, textiles, transportation, manufacturing, and agriculture.While the nanotech industry as a whole holds promise, it is still in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-inc-nnvc-best-nanotech-162936380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NNVC","BK4139","BK4568"],"gpt_icon":0},{"id":"2510097802","title":"NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape","url":"https://stock-news.laohu8.com/highlight/detail?id=2510097802","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510097802?lang=en_us&edition=fundamental","pubTime":"2025-02-11 19:30","pubTimestamp":1739273400,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc.   declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu virus H5N1 likely cannot escape despite its ability to mutate rapidly with genomic changes.An \"opinion and analysis\" article published in Scientific American on February 7th correctly recognizes that the H5N1 \"virus is versatile…This article's titular declaration that the \"US is not ready for bird flu in humans\" is myopic.We beg to differ from this opinion, and hereby declare that our broad-spectrum antiviral drug NV-387 that H5N1 virus will not be able to escape even as it changes in the field, is ready to fight the battle and save lives, should a human H5N1 pandemic occur.The bird-flu virus and its variants are highly unlikely to escape the broad spectrum, host-mimetic, antiviral drug NV-387, because all of these variants continue to land on the same host-side feature that ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-drug-fight-bird-flu-113000223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2507246684","title":"NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507246684","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507246684?lang=en_us&edition=fundamental","pubTime":"2025-01-29 19:30","pubTimestamp":1738150200,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc.  , a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it is presenting today, January 29, at 11am at the MicroCap Conference 2025 in Atlantic City, NJ.NanoViricides Presentation at the MicroCap Conference, Atlantic City. NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease. The Company has announced that it has engaged a CRO for conducting the Phase II clinical trials in the African Region.The Phase II-ready drug NV-387 has demonstrated extremely broad antiviral spectrum of activity in animal models, which could prove to be as revolutionary for viral infections as penicillin was for bacterial infections. This broad spectrum is because NV-387 is designed to mimic a host-side feature that is used by over 90-95% of human pathogenic virus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanoviricides-present-microcap-conference-wednesday-113000322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NNVC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-15","symbol":"NNVC","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-02-14","symbol":"NNVC","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739509200000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2024-11-14","symbol":"NNVC","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.23},{"market":"US","date":"2024-09-27","symbol":"NNVC","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1727409600000,"reportTimeType":"post","actualEps":-0.19},{"market":"US","date":"2024-05-14","symbol":"NNVC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NNVC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NNVC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NNVC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NNVC","date":"2025-07-18","current":-2.709765,"percent":0.388797,"low":-8.257983,"twenty":-3.426034,"median":-2.448382,"eighty":-2.020561,"high":-1.333135,"avg":-2.875881,"sd":1.279238,"marketCap":26358080},"quantilePoints":[{"date":"2020-07-24","current":-4.928766,"twenty":-11.551315,"median":-6.613011,"eighty":-2.576332,"marketCap":67938699},{"date":"2020-07-31","current":-4.820612,"twenty":-11.551315,"median":-6.52606,"eighty":-2.576332,"marketCap":66447881},{"date":"2020-08-07","current":-4.897865,"twenty":-11.551315,"median":-6.500126,"eighty":-2.576332,"marketCap":67512751},{"date":"2020-08-14","current":-4.434345,"twenty":-11.551315,"median":-6.462701,"eighty":-2.576332,"marketCap":61123532},{"date":"2020-08-21","current":-3.74679,"twenty":-11.551315,"median":-6.417575,"eighty":-2.576332,"marketCap":51646190},{"date":"2020-08-28","current":-3.167389,"twenty":-11.551315,"median":-6.399341,"eighty":-2.576332,"marketCap":43659665},{"date":"2020-09-04","current":-3.314171,"twenty":-11.551315,"median":-6.344807,"eighty":-2.576332,"marketCap":45682918},{"date":"2020-09-11","current":-3.059234,"twenty":-11.551315,"median":-6.317369,"eighty":-2.576332,"marketCap":42168848},{"date":"2020-09-18","current":-3.329621,"twenty":-11.551315,"median":-6.266676,"eighty":-2.576332,"marketCap":45895892},{"date":"2020-09-25","current":-2.95108,"twenty":-11.551315,"median":-6.134843,"eighty":-2.576332,"marketCap":40678030},{"date":"2020-10-02","current":-2.958805,"twenty":-11.551315,"median":-6.079026,"eighty":-2.576332,"marketCap":40784517},{"date":"2020-10-09","current":-3.151938,"twenty":-11.551315,"median":-5.961802,"eighty":-2.576332,"marketCap":43446691},{"date":"2020-10-16","current":-3.10436,"twenty":-11.551315,"median":-5.869747,"eighty":-2.576332,"marketCap":41742900},{"date":"2020-10-23","current":-3.088522,"twenty":-11.551315,"median":-5.80821,"eighty":-2.576332,"marketCap":41529926},{"date":"2020-10-30","current":-2.731323,"twenty":-11.551315,"median":-5.763677,"eighty":-2.576332,"marketCap":36726837},{"date":"2020-11-06","current":-2.73924,"twenty":-11.551315,"median":-5.704394,"eighty":-2.576332,"marketCap":36833291},{"date":"2020-11-13","current":-2.778824,"twenty":-11.551315,"median":-5.646071,"eighty":-2.576332,"marketCap":37365564},{"date":"2020-11-20","current":-2.817128,"twenty":-11.551315,"median":-5.55316,"eighty":-2.576332,"marketCap":39993750},{"date":"2020-11-27","current":-2.704443,"twenty":-11.551315,"median":-5.550142,"eighty":-2.576332,"marketCap":38394000},{"date":"2020-12-04","current":-2.907276,"twenty":-11.551315,"median":-5.479283,"eighty":-2.576332,"marketCap":41273550},{"date":"2020-12-11","current":-2.606783,"twenty":-11.551315,"median":-5.436362,"eighty":-2.576332,"marketCap":37007550},{"date":"2020-12-18","current":-2.636832,"twenty":-11.551315,"median":-5.410581,"eighty":-2.576332,"marketCap":37434150},{"date":"2020-12-24","current":-2.636832,"twenty":-11.551315,"median":-5.369111,"eighty":-2.576332,"marketCap":37434150},{"date":"2020-12-31","current":-2.156042,"twenty":-11.481307,"median":-5.329042,"eighty":-2.551389,"marketCap":30608550},{"date":"2021-01-08","current":-2.464048,"twenty":-11.481307,"median":-5.269538,"eighty":-2.537233,"marketCap":34981200},{"date":"2021-01-15","current":-2.464048,"twenty":-11.481307,"median":-5.232807,"eighty":-2.519791,"marketCap":34981200},{"date":"2021-01-22","current":-3.327968,"twenty":-11.481307,"median":-5.222018,"eighty":-2.519791,"marketCap":47245950},{"date":"2021-01-29","current":-3.034986,"twenty":-11.481307,"median":-5.155523,"eighty":-2.519791,"marketCap":43086600},{"date":"2021-02-05","current":-3.538313,"twenty":-11.4113,"median":-5.109511,"eighty":-2.519791,"marketCap":50232150},{"date":"2021-02-12","current":-3.78622,"twenty":-11.341292,"median":-5.07155,"eighty":-2.519791,"marketCap":53751600},{"date":"2021-02-19","current":-3.620149,"twenty":-11.311529,"median":-5.024525,"eighty":-2.519791,"marketCap":52851150},{"date":"2021-02-26","current":-3.057014,"twenty":-11.271284,"median":-5.00388,"eighty":-2.519791,"marketCap":44629860},{"date":"2021-03-05","current":-3.876119,"twenty":-11.177066,"median":-4.973773,"eighty":-2.518657,"marketCap":56588100},{"date":"2021-03-12","current":-3.817611,"twenty":-11.075262,"median":-4.952574,"eighty":-2.518657,"marketCap":55733940},{"date":"2021-03-19","current":-3.678656,"twenty":-10.947439,"median":-4.928766,"eighty":-2.518657,"marketCap":53705310},{"date":"2021-03-26","current":-3.605522,"twenty":-10.921244,"median":-4.89353,"eighty":-2.519791,"marketCap":52637610},{"date":"2021-04-01","current":-3.47388,"twenty":-10.851236,"median":-4.872521,"eighty":-2.519791,"marketCap":50715750},{"date":"2021-04-09","current":-3.408059,"twenty":-10.781228,"median":-4.831249,"eighty":-2.518657,"marketCap":49754820},{"date":"2021-04-16","current":-3.00582,"twenty":-10.596948,"median":-4.785979,"eighty":-2.518657,"marketCap":43882470},{"date":"2021-04-23","current":-3.057014,"twenty":-10.508695,"median":-4.726099,"eighty":-2.518657,"marketCap":44629860},{"date":"2021-04-30","current":-3.035074,"twenty":-10.404778,"median":-4.666105,"eighty":-2.518657,"marketCap":44309550},{"date":"2021-05-07","current":-2.654776,"twenty":-9.700722,"median":-4.544321,"eighty":-2.518657,"marketCap":38757510},{"date":"2021-05-14","current":-4.562569,"twenty":-9.419194,"median":-4.510132,"eighty":-2.506117,"marketCap":39347100},{"date":"2021-05-21","current":-4.776022,"twenty":-9.231528,"median":-4.510132,"eighty":-2.506117,"marketCap":41187900},{"date":"2021-05-28","current":-4.789363,"twenty":-9.074029,"median":-4.510132,"eighty":-2.506117,"marketCap":41302950},{"date":"2021-06-04","current":-5.002817,"twenty":-9.026854,"median":-4.518582,"eighty":-2.509122,"marketCap":43143750},{"date":"2021-06-11","current":-5.883312,"twenty":-8.963729,"median":-4.518582,"eighty":-2.509122,"marketCap":50737050},{"date":"2021-06-18","current":-5.082862,"twenty":-8.899973,"median":-4.518582,"eighty":-2.509122,"marketCap":43834050},{"date":"2021-06-25","current":-6.216833,"twenty":-8.83748,"median":-4.518582,"eighty":-2.509122,"marketCap":53613300},{"date":"2021-07-02","current":-5.736563,"twenty":-8.774355,"median":-4.518582,"eighty":-2.509122,"marketCap":49471500},{"date":"2021-07-09","current":-5.576473,"twenty":-8.71123,"median":-4.518582,"eighty":-2.509122,"marketCap":48090900},{"date":"2021-07-16","current":-5.242952,"twenty":-8.71123,"median":-4.518582,"eighty":-2.509122,"marketCap":45214650},{"date":"2021-07-23","current":-5.656518,"twenty":-8.672078,"median":-4.518582,"eighty":-2.509122,"marketCap":48781200},{"date":"2021-07-30","current":-5.363019,"twenty":-8.648105,"median":-4.518582,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-08-06","current":-5.21627,"twenty":-8.605807,"median":-4.518582,"eighty":-2.509122,"marketCap":44984550},{"date":"2021-08-13","current":-5.069521,"twenty":-8.58498,"median":-4.518582,"eighty":-2.509122,"marketCap":43719000},{"date":"2021-08-20","current":-4.949453,"twenty":-8.521855,"median":-4.518582,"eighty":-2.509122,"marketCap":42683550},{"date":"2021-08-27","current":-5.136225,"twenty":-8.381184,"median":-4.527033,"eighty":-2.509122,"marketCap":44294250},{"date":"2021-09-03","current":-5.363019,"twenty":-8.332481,"median":-4.527335,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-09-10","current":-5.256293,"twenty":-8.269356,"median":-4.527335,"eighty":-2.509122,"marketCap":45329700},{"date":"2021-09-17","current":-5.363019,"twenty":-8.206231,"median":-4.527335,"eighty":-2.509122,"marketCap":46250100},{"date":"2021-09-24","current":-6.777149,"twenty":-8.180981,"median":-4.527335,"eighty":-2.509122,"marketCap":58445400},{"date":"2021-10-01","current":-5.869971,"twenty":-8.079981,"median":-4.527335,"eighty":-2.509122,"marketCap":50622000},{"date":"2021-10-08","current":-5.829949,"twenty":-8.016857,"median":-4.527335,"eighty":-2.509122,"marketCap":50276850},{"date":"2021-10-15","current":-6.36953,"twenty":-8.010675,"median":-4.527335,"eighty":-2.509122,"marketCap":56193200},{"date":"2021-10-22","current":-6.304269,"twenty":-7.953732,"median":-4.527335,"eighty":-2.509122,"marketCap":55617450},{"date":"2021-10-29","current":-6.186798,"twenty":-7.94329,"median":-4.527335,"eighty":-2.509122,"marketCap":54581100},{"date":"2021-11-05","current":-6.173746,"twenty":-7.890607,"median":-4.527335,"eighty":-2.509122,"marketCap":54465950},{"date":"2021-11-12","current":-6.095432,"twenty":-7.788302,"median":-4.527335,"eighty":-2.509122,"marketCap":53775050},{"date":"2021-11-19","current":-5.797853,"twenty":-7.663997,"median":-4.527335,"eighty":-2.509122,"marketCap":52899750},{"date":"2021-11-26","current":-6.138903,"twenty":-7.585674,"median":-4.527335,"eighty":-2.509122,"marketCap":56011500},{"date":"2021-12-03","current":-5.633644,"twenty":-7.428051,"median":-4.527335,"eighty":-2.509122,"marketCap":51401500},{"date":"2021-12-10","current":-5.406277,"twenty":-7.300703,"median":-4.527335,"eighty":-2.509122,"marketCap":49327000},{"date":"2021-12-17","current":-5.229436,"twenty":-7.180968,"median":-4.527335,"eighty":-2.509122,"marketCap":47713500},{"date":"2021-12-23","current":-4.976806,"twenty":-7.079181,"median":-4.527335,"eighty":-2.509122,"marketCap":45408500},{"date":"2021-12-31","current":-4.698914,"twenty":-6.987904,"median":-4.527335,"eighty":-2.509122,"marketCap":42873000},{"date":"2022-01-07","current":-3.890498,"twenty":-6.926651,"median":-4.436412,"eighty":-2.509122,"marketCap":35497000},{"date":"2022-01-14","current":-3.675763,"twenty":-6.89782,"median":-4.401483,"eighty":-2.509122,"marketCap":33537750},{"date":"2022-01-21","current":-2.905242,"twenty":-6.846702,"median":-4.310739,"eighty":-2.509122,"marketCap":26507500},{"date":"2022-01-28","current":-2.728401,"twenty":-6.779582,"median":-4.173405,"eighty":-2.509122,"marketCap":24894000},{"date":"2022-02-04","current":-3.05682,"twenty":-6.712109,"median":-4.02803,"eighty":-2.509122,"marketCap":27890500},{"date":"2022-02-11","current":-2.854716,"twenty":-6.637806,"median":-3.995999,"eighty":-2.509122,"marketCap":26046500},{"date":"2022-02-18","current":-2.62043,"twenty":-6.580578,"median":-3.946834,"eighty":-2.509122,"marketCap":22837320},{"date":"2022-02-25","current":-2.646899,"twenty":-6.52606,"median":-3.923893,"eighty":-2.509122,"marketCap":23068000},{"date":"2022-03-04","current":-2.50132,"twenty":-6.496806,"median":-3.868397,"eighty":-2.507562,"marketCap":21799260},{"date":"2022-03-11","current":-2.448382,"twenty":-6.462701,"median":-3.821268,"eighty":-2.492597,"marketCap":21337900},{"date":"2022-03-18","current":-2.964527,"twenty":-6.435992,"median":-3.787617,"eighty":-2.484025,"marketCap":25836160},{"date":"2022-03-25","current":-3.096872,"twenty":-6.399341,"median":-3.766488,"eighty":-2.484025,"marketCap":26989560},{"date":"2022-04-01","current":-2.73954,"twenty":-6.395635,"median":-3.735019,"eighty":-2.484025,"marketCap":23875380},{"date":"2022-04-08","current":-2.593961,"twenty":-6.356646,"median":-3.703835,"eighty":-2.484025,"marketCap":22606640},{"date":"2022-04-14","current":-2.501584,"twenty":-6.335311,"median":-3.656716,"eighty":-2.482663,"marketCap":21801566},{"date":"2022-04-22","current":-2.223395,"twenty":-6.304269,"median":-3.638432,"eighty":-2.478152,"marketCap":19377120},{"date":"2022-04-29","current":-1.97194,"twenty":-6.279718,"median":-3.579246,"eighty":-2.47116,"marketCap":17185660},{"date":"2022-05-06","current":-1.97194,"twenty":-6.219501,"median":-3.523708,"eighty":-2.460477,"marketCap":17185660},{"date":"2022-05-13","current":-1.710426,"twenty":-6.176384,"median":-3.477537,"eighty":-2.45259,"marketCap":14906541},{"date":"2022-05-20","current":-3.57635,"twenty":-6.112925,"median":-3.448283,"eighty":-2.44683,"marketCap":30040400},{"date":"2022-05-27","current":-2.957366,"twenty":-6.0948,"median":-3.404402,"eighty":-2.44683,"marketCap":24841100},{"date":"2022-06-03","current":-2.751038,"twenty":-6.063146,"median":-3.382022,"eighty":-2.44683,"marketCap":23108000},{"date":"2022-06-10","current":-2.778549,"twenty":-6.021887,"median":-3.36235,"eighty":-2.44683,"marketCap":23339080},{"date":"2022-06-17","current":-2.764793,"twenty":-5.978029,"median":-3.327968,"eighty":-2.44683,"marketCap":23223540},{"date":"2022-06-24","current":-2.806059,"twenty":-5.953332,"median":-3.30945,"eighty":-2.445278,"marketCap":23570160},{"date":"2022-07-01","current":-2.599731,"twenty":-5.898451,"median":-3.23985,"eighty":-2.445278,"marketCap":21837060},{"date":"2022-07-08","current":-3.148563,"twenty":-5.871439,"median":-3.219656,"eighty":-2.445278,"marketCap":26447106},{"date":"2022-07-15","current":-2.737283,"twenty":-5.837732,"median":-3.192745,"eighty":-2.445278,"marketCap":22992460},{"date":"2022-07-22","current":-2.874835,"twenty":-5.807263,"median":-3.167389,"eighty":-2.445278,"marketCap":24147860},{"date":"2022-07-29","current":-2.503445,"twenty":-5.78537,"median":-3.144776,"eighty":-2.440257,"marketCap":21028280},{"date":"2022-08-05","current":-4.869338,"twenty":-5.744619,"median":-3.132647,"eighty":-2.440257,"marketCap":40901160},{"date":"2022-08-12","current":-3.823943,"twenty":-5.727928,"median":-3.132647,"eighty":-2.440257,"marketCap":32120120},{"date":"2022-08-19","current":-3.342511,"twenty":-5.684312,"median":-3.132647,"eighty":-2.440257,"marketCap":28076220},{"date":"2022-08-26","current":-3.094918,"twenty":-5.661854,"median":-3.132245,"eighty":-2.440257,"marketCap":25996500},{"date":"2022-09-02","current":-2.902345,"twenty":-5.581809,"median":-3.128118,"eighty":-2.440257,"marketCap":24378940},{"date":"2022-09-09","current":-2.984876,"twenty":-5.560806,"median":-3.117013,"eighty":-2.440257,"marketCap":25072180},{"date":"2022-09-16","current":-2.668507,"twenty":-5.55316,"median":-3.10436,"eighty":-2.440257,"marketCap":22414760},{"date":"2022-09-23","current":-2.14581,"twenty":-5.519162,"median":-3.095823,"eighty":-2.439684,"marketCap":18024240},{"date":"2022-09-30","current":-2.379648,"twenty":-5.477266,"median":-3.088522,"eighty":-2.439647,"marketCap":19988420},{"date":"2022-10-07","current":-2.132055,"twenty":-5.456405,"median":-3.080603,"eighty":-2.439647,"marketCap":17908700},{"date":"2022-10-14","current":-2.502362,"twenty":-5.43594,"median":-3.072683,"eighty":-2.437394,"marketCap":20286302},{"date":"2022-10-21","current":-2.402267,"twenty":-5.421719,"median":-3.06696,"eighty":-2.434784,"marketCap":19474850},{"date":"2022-10-28","current":-2.359369,"twenty":-5.377446,"median":-3.06013,"eighty":-2.430342,"marketCap":19127085},{"date":"2022-11-04","current":-2.334363,"twenty":-5.363019,"median":-3.057014,"eighty":-2.4206,"marketCap":18924360},{"date":"2022-11-11","current":-2.477575,"twenty":-5.336338,"median":-3.043934,"eighty":-2.417533,"marketCap":20085364},{"date":"2022-11-18","current":-2.711681,"twenty":-5.332826,"median":-3.036058,"eighty":-2.417533,"marketCap":19156500},{"date":"2022-11-25","current":-2.760984,"twenty":-5.332826,"median":-3.034986,"eighty":-2.417533,"marketCap":19504800},{"date":"2022-12-02","current":-2.777419,"twenty":-5.332826,"median":-3.028333,"eighty":-2.417533,"marketCap":19620900},{"date":"2022-12-09","current":-2.39121,"twenty":-5.292381,"median":-3.026142,"eighty":-2.416192,"marketCap":16892550},{"date":"2022-12-16","current":-2.087173,"twenty":-5.292381,"median":-3.018926,"eighty":-2.406742,"marketCap":14744700},{"date":"2022-12-23","current":-1.972132,"twenty":-5.292381,"median":-3.00582,"eighty":-2.395506,"marketCap":13932000},{"date":"2022-12-30","current":-1.824222,"twenty":-5.292381,"median":-2.997432,"eighty":-2.389879,"marketCap":12887100},{"date":"2023-01-06","current":-2.202214,"twenty":-5.277173,"median":-2.989706,"eighty":-2.387968,"marketCap":15557400},{"date":"2023-01-13","current":-2.333853,"twenty":-5.260084,"median":-2.981981,"eighty":-2.376115,"marketCap":16487361},{"date":"2023-01-20","current":-2.30082,"twenty":-5.250996,"median":-2.973783,"eighty":-2.373517,"marketCap":16254000},{"date":"2023-01-27","current":-2.399427,"twenty":-5.240028,"median":-2.96653,"eighty":-2.370947,"marketCap":16950600},{"date":"2023-02-03","current":-2.284386,"twenty":-5.221675,"median":-2.956693,"eighty":-2.366583,"marketCap":16137900},{"date":"2023-02-10","current":-2.276169,"twenty":-5.202929,"median":-2.950137,"eighty":-2.360695,"marketCap":16079850},{"date":"2023-02-17","current":-2.44914,"twenty":-5.171998,"median":-2.943354,"eighty":-2.359369,"marketCap":16870750},{"date":"2023-02-24","current":-2.128219,"twenty":-5.154465,"median":-2.937326,"eighty":-2.348627,"marketCap":14660100},{"date":"2023-03-03","current":-2.330906,"twenty":-5.122989,"median":-2.92765,"eighty":-2.343232,"marketCap":16056300},{"date":"2023-03-10","current":-2.145109,"twenty":-5.087088,"median":-2.913716,"eighty":-2.342061,"marketCap":14776450},{"date":"2023-03-17","current":-2.195781,"twenty":-5.05618,"median":-2.905242,"eighty":-2.334159,"marketCap":15125500},{"date":"2023-03-24","current":-2.094437,"twenty":-5.017952,"median":-2.902345,"eighty":-2.329408,"marketCap":14427400},{"date":"2023-03-31","current":-1.97975,"twenty":-5.017055,"median":-2.891819,"eighty":-2.325041,"marketCap":13637383},{"date":"2023-04-06","current":-2.753172,"twenty":-5.017055,"median":-2.888698,"eighty":-2.322276,"marketCap":18965050},{"date":"2023-04-14","current":-1.993094,"twenty":-5.017952,"median":-2.874835,"eighty":-2.316037,"marketCap":13729300},{"date":"2023-04-21","current":-2.263344,"twenty":-5.002368,"median":-2.859591,"eighty":-2.313801,"marketCap":15590900},{"date":"2023-04-28","current":-2.280234,"twenty":-5.002368,"median":-2.849614,"eighty":-2.312786,"marketCap":15707250},{"date":"2023-05-05","current":-2.077547,"twenty":-5.002368,"median":-2.840873,"eighty":-2.302937,"marketCap":14311050},{"date":"2023-05-11","current":-2.043766,"twenty":-5.002368,"median":-2.835777,"eighty":-2.30082,"marketCap":14078350},{"date":"2023-05-19","current":-1.920317,"twenty":-5.002518,"median":-2.832097,"eighty":-2.294808,"marketCap":13055420},{"date":"2023-05-26","current":-1.887542,"twenty":-5.002667,"median":-2.817128,"eighty":-2.284962,"marketCap":12832600},{"date":"2023-06-02","current":-2.239311,"twenty":-5.002667,"median":-2.810544,"eighty":-2.283362,"marketCap":15224130},{"date":"2023-06-09","current":-1.973339,"twenty":-5.002817,"median":-2.806059,"eighty":-2.276679,"marketCap":13415900},{"date":"2023-06-16","current":-1.870383,"twenty":-5.008153,"median":-2.792391,"eighty":-2.269675,"marketCap":12715940},{"date":"2023-06-23","current":-1.921861,"twenty":-5.010821,"median":-2.779567,"eighty":-2.263344,"marketCap":13065920},{"date":"2023-06-30","current":-2.144934,"twenty":-5.017055,"median":-2.778549,"eighty":-2.263295,"marketCap":14582500},{"date":"2023-07-06","current":-2.024818,"twenty":-5.017952,"median":-2.777419,"eighty":-2.259272,"marketCap":13765880},{"date":"2023-07-14","current":-2.488124,"twenty":-5.020645,"median":-2.769833,"eighty":-2.254292,"marketCap":16915700},{"date":"2023-07-21","current":-2.745516,"twenty":-5.0361,"median":-2.767019,"eighty":-2.252684,"marketCap":18665600},{"date":"2023-07-27","current":-2.676878,"twenty":-5.039964,"median":-2.764793,"eighty":-2.252282,"marketCap":18198960},{"date":"2023-08-04","current":-2.453805,"twenty":-5.039964,"median":-2.753964,"eighty":-2.252129,"marketCap":16682380},{"date":"2023-08-11","current":-2.219738,"twenty":-5.039964,"median":-2.751307,"eighty":-2.246058,"marketCap":15091061},{"date":"2023-08-18","current":-2.21991,"twenty":-5.039964,"median":-2.751307,"eighty":-2.244476,"marketCap":15092230},{"date":"2023-08-25","current":-2.667127,"twenty":-5.039964,"median":-2.753168,"eighty":-2.251186,"marketCap":18132670},{"date":"2023-09-01","current":-2.495054,"twenty":-5.039964,"median":-2.751038,"eighty":-2.251186,"marketCap":16962820},{"date":"2023-09-08","current":-2.340189,"twenty":-5.039964,"median":-2.74376,"eighty":-2.251186,"marketCap":15909955},{"date":"2023-09-15","current":-2.288567,"twenty":-5.039964,"median":-2.738088,"eighty":-2.246453,"marketCap":15559001},{"date":"2023-09-22","current":-2.185324,"twenty":-5.039964,"median":-2.725967,"eighty":-2.236945,"marketCap":14857091},{"date":"2023-09-29","current":-2.426225,"twenty":-5.039964,"median":-2.723609,"eighty":-2.236573,"marketCap":16494880},{"date":"2023-10-06","current":-2.254153,"twenty":-5.039964,"median":-2.723609,"eighty":-2.234464,"marketCap":15325031},{"date":"2023-10-13","current":-2.013251,"twenty":-5.039964,"median":-2.723467,"eighty":-2.230216,"marketCap":13687241},{"date":"2023-10-20","current":-1.572776,"twenty":-5.039964,"median":-2.723467,"eighty":-2.222732,"marketCap":13507900},{"date":"2023-10-27","current":-1.600128,"twenty":-5.039964,"median":-2.72369,"eighty":-2.219772,"marketCap":13742820},{"date":"2023-11-03","current":-1.5591,"twenty":-5.039964,"median":-2.72369,"eighty":-2.211571,"marketCap":13390440},{"date":"2023-11-10","current":-1.463365,"twenty":-5.039964,"median":-2.718749,"eighty":-2.202243,"marketCap":12568220},{"date":"2023-11-17","current":-1.487026,"twenty":-5.039964,"median":-2.715489,"eighty":-2.195907,"marketCap":13363424},{"date":"2023-11-24","current":-1.359275,"twenty":-5.039964,"median":-2.713071,"eighty":-2.189723,"marketCap":12215368},{"date":"2023-12-01","current":-1.503045,"twenty":-5.039964,"median":-2.709773,"eighty":-2.185324,"marketCap":13507379},{"date":"2023-12-08","current":-1.50958,"twenty":-5.039964,"median":-2.70214,"eighty":-2.168223,"marketCap":13566106},{"date":"2023-12-15","current":-1.489975,"twenty":-5.039964,"median":-2.696474,"eighty":-2.162,"marketCap":13389923},{"date":"2023-12-22","current":-1.385415,"twenty":-5.039964,"median":-2.696474,"eighty":-2.156514,"marketCap":12450279},{"date":"2023-12-29","current":-1.398485,"twenty":-5.039964,"median":-2.696931,"eighty":-2.156278,"marketCap":12567735},{"date":"2024-01-05","current":-1.424625,"twenty":-5.039964,"median":-2.698293,"eighty":-2.150909,"marketCap":12802646},{"date":"2024-01-12","current":-1.353525,"twenty":-5.039964,"median":-2.698293,"eighty":-2.145109,"marketCap":12163688},{"date":"2024-01-19","current":-1.359275,"twenty":-5.043083,"median":-2.699655,"eighty":-2.135592,"marketCap":12215368},{"date":"2024-01-26","current":-1.385415,"twenty":-5.039964,"median":-2.698293,"eighty":-2.120042,"marketCap":12450279},{"date":"2024-02-02","current":-1.476905,"twenty":-5.039964,"median":-2.698293,"eighty":-2.111328,"marketCap":13272468},{"date":"2024-02-09","current":-1.516115,"twenty":-5.039964,"median":-2.687524,"eighty":-2.094437,"marketCap":13624834},{"date":"2024-02-16","current":-1.498107,"twenty":-5.039964,"median":-2.682084,"eighty":-2.081184,"marketCap":14017010},{"date":"2024-02-23","current":-1.59882,"twenty":-5.039964,"median":-2.676392,"eighty":-2.064581,"marketCap":14959330},{"date":"2024-03-01","current":-1.699533,"twenty":-5.0361,"median":-2.668507,"eighty":-2.049674,"marketCap":15901650},{"date":"2024-03-08","current":-1.422572,"twenty":-5.0361,"median":-2.666881,"eighty":-2.03312,"marketCap":13310270},{"date":"2024-03-15","current":-1.472929,"twenty":-5.0361,"median":-2.656354,"eighty":-2.014962,"marketCap":13781430},{"date":"2024-03-22","current":-1.435162,"twenty":-5.0361,"median":-2.651857,"eighty":-1.997134,"marketCap":13428060},{"date":"2024-03-28","current":-1.422572,"twenty":-5.0361,"median":-2.646899,"eighty":-1.988953,"marketCap":13310270},{"date":"2024-04-05","current":-1.724712,"twenty":-5.039964,"median":-2.645782,"eighty":-1.976203,"marketCap":16137230},{"date":"2024-04-12","current":-1.59882,"twenty":-5.039964,"median":-2.640997,"eighty":-1.967997,"marketCap":14959330},{"date":"2024-04-19","current":-1.479223,"twenty":-5.039964,"median":-2.636576,"eighty":-1.942422,"marketCap":13840325},{"date":"2024-04-26","current":-1.397394,"twenty":-5.0361,"median":-2.625126,"eighty":-1.921861,"marketCap":13074690},{"date":"2024-05-03","current":-1.510696,"twenty":-5.0361,"median":-2.62043,"eighty":-1.908491,"marketCap":14134800},{"date":"2024-05-10","current":-2.303812,"twenty":-5.0361,"median":-2.62043,"eighty":-1.904702,"marketCap":21555570},{"date":"2024-05-17","current":-2.762595,"twenty":-5.0361,"median":-2.63632,"eighty":-1.904702,"marketCap":26267170},{"date":"2024-05-24","current":-2.762595,"twenty":-5.0361,"median":-2.640997,"eighty":-1.904702,"marketCap":26267170},{"date":"2024-05-31","current":-3.010361,"twenty":-5.0361,"median":-2.645943,"eighty":-1.904702,"marketCap":28622970},{"date":"2024-06-07","current":-3.282904,"twenty":-5.0361,"median":-2.651857,"eighty":-1.904702,"marketCap":31214350},{"date":"2024-06-14","current":-3.205683,"twenty":-5.039964,"median":-2.663299,"eighty":-1.904702,"marketCap":30480120},{"date":"2024-06-21","current":-2.522301,"twenty":-5.039964,"median":-2.666881,"eighty":-1.904582,"marketCap":23982420},{"date":"2024-06-28","current":-2.149547,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20438220},{"date":"2024-07-05","current":-2.186822,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20792640},{"date":"2024-07-12","current":-2.236523,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":21265200},{"date":"2024-07-15","current":-2.161972,"twenty":-5.039964,"median":-2.667004,"eighty":-1.904221,"marketCap":20556360},{"date":"2024-08-02","current":-2.609277,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":24809400},{"date":"2024-08-09","current":-2.360774,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":22446600},{"date":"2024-08-16","current":-2.360774,"twenty":-5.05618,"median":-2.674394,"eighty":-1.887542,"marketCap":22446600},{"date":"2024-08-23","current":-2.286223,"twenty":-5.05618,"median":-2.675731,"eighty":-1.887542,"marketCap":21737760},{"date":"2024-08-30","current":-2.335924,"twenty":-5.05618,"median":-2.675731,"eighty":-1.890067,"marketCap":22210320},{"date":"2024-09-06","current":-2.224098,"twenty":-5.05618,"median":-2.675731,"eighty":-1.890067,"marketCap":21147060},{"date":"2024-09-13","current":-2.087421,"twenty":-5.05618,"median":-2.675731,"eighty":-1.899521,"marketCap":19847520},{"date":"2024-09-20","current":-1.96317,"twenty":-5.05618,"median":-2.675731,"eighty":-1.917578,"marketCap":18666120},{"date":"2024-09-27","current":-1.764368,"twenty":-5.05618,"median":-2.675731,"eighty":-1.921243,"marketCap":16775880},{"date":"2024-10-04","current":-2.008373,"twenty":-5.05618,"median":-2.675731,"eighty":-1.947416,"marketCap":16657740},{"date":"2024-10-11","current":-1.951398,"twenty":-5.05618,"median":-2.675731,"eighty":-1.961627,"marketCap":16185180},{"date":"2024-10-18","current":-2.122323,"twenty":-5.05618,"median":-2.675731,"eighty":-1.972856,"marketCap":17602860},{"date":"2024-10-25","current":-2.122323,"twenty":-5.05618,"median":-2.675731,"eighty":-1.978331,"marketCap":17602860},{"date":"2024-10-31","current":-1.937154,"twenty":-5.05618,"median":-2.675731,"eighty":-1.988348,"marketCap":16067040},{"date":"2024-11-08","current":-2.122323,"twenty":-5.05618,"median":-2.675818,"eighty":-2.003331,"marketCap":17602860},{"date":"2024-11-15","current":-1.908667,"twenty":-5.05618,"median":-2.675818,"eighty":-2.007658,"marketCap":15830760},{"date":"2024-11-22","current":-1.599829,"twenty":-5.05618,"median":-2.675818,"eighty":-2.007658,"marketCap":15121920},{"date":"2024-11-29","current":-2.06427,"twenty":-5.05618,"median":-2.675818,"eighty":-2.022617,"marketCap":19511920},{"date":"2024-12-06","current":-2.216055,"twenty":-5.05618,"median":-2.675818,"eighty":-2.028308,"marketCap":20946620},{"date":"2024-12-13","current":-2.231234,"twenty":-5.05618,"median":-2.675818,"eighty":-2.043766,"marketCap":21090090},{"date":"2024-12-20","current":-2.200877,"twenty":-5.05618,"median":-2.675818,"eighty":-2.051201,"marketCap":20803150},{"date":"2024-12-27","current":-2.291947,"twenty":-5.05618,"median":-2.675818,"eighty":-2.063251,"marketCap":21663970},{"date":"2025-01-03","current":-2.155341,"twenty":-5.05618,"median":-2.675818,"eighty":-2.067504,"marketCap":20372740},{"date":"2025-01-10","current":-2.109806,"twenty":-5.05618,"median":-2.675905,"eighty":-2.079813,"marketCap":19942330},{"date":"2025-01-17","current":-1.821415,"twenty":-5.05618,"median":-2.675905,"eighty":-2.079813,"marketCap":17216400},{"date":"2025-01-24","current":-1.699987,"twenty":-5.05618,"median":-2.675731,"eighty":-2.077956,"marketCap":16068640},{"date":"2025-01-31","current":-1.624095,"twenty":-5.019747,"median":-2.668507,"eighty":-2.064332,"marketCap":15351290},{"date":"2025-02-07","current":-1.86695,"twenty":-4.974978,"median":-2.666881,"eighty":-2.051347,"marketCap":17646810},{"date":"2025-02-14","current":-1.958021,"twenty":-4.948211,"median":-2.651857,"eighty":-2.049178,"marketCap":18507630},{"date":"2025-02-21","current":-2.42188,"twenty":-4.923399,"median":-2.645943,"eighty":-2.049178,"marketCap":22680335},{"date":"2025-02-28","current":-2.238151,"twenty":-4.869408,"median":-2.636832,"eighty":-2.049178,"marketCap":20959758},{"date":"2025-03-07","current":-2.204746,"twenty":-4.859238,"median":-2.619088,"eighty":-2.043766,"marketCap":20646926},{"date":"2025-03-14","current":-2.021017,"twenty":-4.814317,"median":-2.611175,"eighty":-2.043766,"marketCap":18926349},{"date":"2025-03-21","current":-2.204746,"twenty":-4.762681,"median":-2.603257,"eighty":-2.043766,"marketCap":20646926},{"date":"2025-03-28","current":-2.021017,"twenty":-4.736,"median":-2.593961,"eighty":-2.037721,"marketCap":18926349},{"date":"2025-04-04","current":-1.904099,"twenty":-4.695977,"median":-2.574477,"eighty":-2.024878,"marketCap":17831436},{"date":"2025-04-11","current":-1.78718,"twenty":-4.601221,"median":-2.559576,"eighty":-2.021017,"marketCap":16736523},{"date":"2025-04-17","current":-2.338367,"twenty":-4.561033,"median":-2.554258,"eighty":-2.021017,"marketCap":21898255},{"date":"2025-04-25","current":-2.254854,"twenty":-4.395718,"median":-2.539152,"eighty":-2.021017,"marketCap":21116174},{"date":"2025-05-02","current":-2.221448,"twenty":-4.236599,"median":-2.517715,"eighty":-2.021017,"marketCap":20803342},{"date":"2025-05-09","current":-2.355069,"twenty":-4.022387,"median":-2.509122,"eighty":-2.021017,"marketCap":22054671},{"date":"2025-05-16","current":-2.188043,"twenty":-3.94774,"median":-2.501973,"eighty":-2.021017,"marketCap":20490510},{"date":"2025-05-23","current":-2.379913,"twenty":-3.876119,"median":-2.498632,"eighty":-2.021017,"marketCap":23149584},{"date":"2025-05-30","current":-2.524637,"twenty":-3.823943,"median":-2.498632,"eighty":-2.021017,"marketCap":24557329},{"date":"2025-06-06","current":-2.395993,"twenty":-3.78622,"median":-2.493989,"eighty":-2.021017,"marketCap":23306000},{"date":"2025-06-13","current":-2.494967,"twenty":-3.754515,"median":-2.493989,"eighty":-2.021017,"marketCap":24268720},{"date":"2025-06-20","current":-2.214076,"twenty":-3.676342,"median":-2.479073,"eighty":-2.020561,"marketCap":21536480},{"date":"2025-06-27","current":-2.032324,"twenty":-3.636238,"median":-2.464048,"eighty":-2.020561,"marketCap":19768560},{"date":"2025-07-03","current":-2.280168,"twenty":-3.554341,"median":-2.459464,"eighty":-2.020561,"marketCap":22179360},{"date":"2025-07-11","current":-2.329737,"twenty":-3.48487,"median":-2.44873,"eighty":-2.020561,"marketCap":22661520},{"date":"2025-07-18","current":-2.709765,"twenty":-3.426034,"median":-2.448382,"eighty":-2.020561,"marketCap":26358080}],"updateTime":1753068122868}}}